A Retrospective Observational Study of Ibrutinib in Real-Life Settings in France, Using the SNDS Database (OSIRIS)


de Pouvourville G1, Choquet S2, Marchal C3, Belhassen M4, Jacoud F3, Guilmet C5, Dupuis S6, Pierres M6, Levy V7
1ESSEC Business School, Cergy Pontoise, France, 2Hôpital Pitié-Salpêtrière, Paris, France, 3PELyon, Lyon, 69, France, 4PELyon, Lyon, France, 5Janssen Cilag France, Issy-les-moulineaux, 92, France, 6Janssen Cilag France, Issy-les-moulineaux, France, 7Hôpital Avicenne AP-HP, Bobigny, France

Presentation Documents

OBJECTIVES : Ibrutinib is a Bruton's Tyrosine Kinase Inhibitor indicated for the treatment of several B-cell malignancies: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Waldenström’s Macroglobulinemia (WM). Medical resource utilization (MRU) and associated costs for patients treated with ibrutinib in France in real-life settings are unknown and need to be examined.

METHODS : All patients affiliated with the general scheme (around 80% of the French population) with a first dispensing of ibrutinib from August 1, 2017 (date of reimbursement in France) to December 31, 2018 were identified in the French national health insurance database (SNDS). Indications for which ibrutinib was supposed to be used were defined by an algorithm based on ICD-10 codes to identify the disease (CLL, MCL or WM), and on codes of previous and concomitant dispensed drugs to understand treatment line (first line –L1– or second or later line –L2+) and therapeutic combination (monotherapy or combination). Costs were described per month from a collective perspective for each indication and by categories (medications, hospitalizations and others).

RESULTS : The population consisted of 2,235 patients who initiated ibrutinib in the first 18 months of the Marketing Authorization in France. The total monthly costs were respectively €6,203, €6,526, €8,579, €6,432 in CLL L1 monotherapy (N=121), CLL L2+ monotherapy (N=853), MCL L2+ monotherapy (N=215) and WM L2+ monotherapy (N=243). These costs were mainly driven by the costs of disease-specific cancer treatment (between 87.3% and 92.2% of total cost) and hospitalization costs. The most frequent MRU will be presented in the poster.

CONCLUSIONS : This is the first study estimating the costs for patients with CLL, MCL and WM, treated with ibrutinib in France. However, no distinction could be made between costs specific to the management of these diseases and those related to comorbidities. Future analyses using data from 2019 and 2020 will be made to update results.

Conference/Value in Health Info

2021-11, ISPOR Europe 2021, Copenhagen, Denmark

Value in Health, Volume 24, Issue 12, S2 (December 2021)




Economic Evaluation, Health Service Delivery & Process of Care, Real World Data & Information Systems

Topic Subcategory

Health & Insurance Records Systems, Treatment Patterns and Guidelines


Drugs, Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now